Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (NVS)
NYSE:NVS
Earnings Data
Report Date
Apr 28, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
2.11Last Year’s EPS
2.28Same Quarter Last Year
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong multi-product commercial momentum, record profitability and cash generation, and a robust late-stage pipeline with multiple potential catalysts in 2026. Management acknowledged notable near-term headwinds — chiefly mid-2025 generic entries (Entresto, Promacta, Tasigna), noisy Q4 gross-to-net adjustments, the largest GX impact expected in 2026, and some clinical/regulatory timing uncertainties (pelacarsen event rates, remibrutinib monitoring, zigakibart timing). However, the breadth of blockbuster growth across key brands, record margins and cash flow, clear capital allocation, and a defined plan to return to 40%+ core margins by 2029 outweigh the near-term challenges.Company Guidance
Full-Year Sales and Profitability
FY2025 sales up 8% (constant currency); Core operating income up 14% to $21.9 billion; achieved 40.1% core margin (target met 2 years early); core EPS up 17% to $8.98; record free cash flow $17.6 billion (+8%).
Kisqali Strong Growth and Market Traction
Kisqali up 57% for the year (Q4 growth 44%; adjusted global growth 54%; U.S. +62% when removing RD adjustments). Management reiterates $10 billion peak sales outlook and notes >60% U.S. eBC NBRx and >80% NBRx share in Germany early breast cancer.
Multiple Blockbuster Brand Performances
Kesimpta +36% to $4.4 billion (expanding first-line adoption to ~50% of NBRx); Pluvicto +42% CC, reached $2 billion (U.S. pre-taxane +75%, PSMA share up 4x to 16%); Scemblix blockbuster with Q4 +87% and 41% U.S. NBRx share across all lines; Leqvio blockbuster (FY +57%, Q4 +46%).
Cosentyx and Specialty Launches
Cosentyx up 8% to $6.7 billion (Q4 +11%); #1 prescribed IL-17 across indications; U.S. growth driven by hidradenitis and IV revenue; U.S. polymyalgia rheumatica submission completed.
Renal Portfolio and Lifecycle Advances
IgAN brands (Vanrafia, Fabhalta) drove 50% of NBRx market growth year-over-year; Fabhalta approved in C3G in 45 countries; management expects full eGFR datasets and filings for Fabhalta and Vanrafia in H1 2026.
Rhapsido Launch Momentum
U.S. launch showing encouraging early demand: >2,000 HCP starts via sampling/bridge program, positive feedback from allergists/dermatologists, expect stronger uptake as access expands (notable pick-up expected in 2H2026).
Pelabresib & Other Pipeline Advances
Pelabresib 96-week MANIFEST data showed deep/durable responses and comparable safety vs ruxolitinib; EU filing path in 2026 and new U.S./China/Japan Phase III planned targeting high-TSS50 patients. Company expects 7 pivotal readouts in 2026 to drive midterm outlook.
Global Health Progress
KLU156 (ganaplacide + lumefantrine) shows strong malaria cure rates (adjusted 99.2% vs 96.4% comparator) and potential to be first new malaria medicine in ~25 years, supporting Novartis' global health mission.
Capital Allocation and Shareholder Returns
Invested >$10 billion in R&D (+8% YoY); completed $15 billion buyback and launched new up-to-$10 billion buyback (≈$7.7 billion remaining); proposing CHF 3.70 dividend (+6% in CHF; 29th consecutive CHF increase).
NVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $149.86 | $152.91 | +2.04% |
Oct 28, 2025 | $129.14 | $123.43 | -4.42% |
Jul 17, 2025 | $118.37 | $114.52 | -3.25% |
Apr 29, 2025 | $112.63 | $113.45 | +0.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novartis Ag (NVS) report earnings?
Novartis Ag (NVS) is schdueled to report earning on Apr 28, 2026, TBA (Confirmed).
What is Novartis Ag (NVS) earnings time?
Novartis Ag (NVS) earnings time is at Apr 28, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVS EPS forecast?
NVS EPS forecast for the fiscal quarter 2026 (Q1) is 2.11.
